Merck said the Phase 3 "Hyperion" study, which was evaluating Winrevair versus placebo in recently diagnosed adults with PAH at intermediate or high risk of disease progression, had lost clinical ...
About 61% of patients with stage I or II dMMR colon cancer achieved a pathologic complete response after a single cycle of neoadjuvant pembrolizumab, new data revealed.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback